Background Opioid use disorder (OUD) negatively impacts the HIV continuum of care for
persons living with HIV (PLH). Medication treatment for OUD (MOUD) may have differential …

Background Opioid use disorder (OUD) negatively impacts the HIV continuum of care for
persons living with HIV. Medication treatment for OUD (MOUD) may have differential …

Abstract Purpose of Review Recent HIV outbreaks have occurred as a result of the current
US opioid epidemic. Providing medications for opioid use disorder (MOUD) with methadone …

Abstract Background Persons with HIV (PWH) and opioid use disorder (OUD) can have poor
health outcomes. We assessed whether intensity of behavioral treatment for OUD (BOUD) …

Background Opioid use disorder (OUD) is prevalent among people with HIV (PWH). Opioid
agonist therapy (OAT) is the most effective treatment for OUD and is associated with …

Although opioid agonist therapy (OAT) is associated with positive health outcomes,
including improved HIV management, long-term retention in OAT remains low among …

Introduction Medications for opioid use disorder (MOUD) include opioid agonist therapies
(OAT)(buprenorphine and methadone), and opioid antagonists (extended-release …

Of the 12 million people who inject drugs worldwide, 13% live with HIV. Whether opioid use
impacts HIV pathogenesis and latency is an outstanding question. To gain insight into …

Objectives: Opioid agonist treatment (OAT) has been shown to improve certain HIV-related
treatment measures among people with HIV (PHIV) with opioid use disorder (OUD) …

Background Associations between fentanyl use and initiation and retention on medications
for opioid use disorder (MOUD) are poorly understood. Methods Data were from a multisite …